Department I of Internal Medicine, Division of Infectious Diseases, University of Cologne, Cologne, Germany.
Faculty of Medicine, Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
EMBO Mol Med. 2021 Jan 11;13(1):e13105. doi: 10.15252/emmm.202013105. Epub 2020 Nov 3.
The ongoing SARS-CoV-2 pandemic stresses the need for effective antiviral drugs that can quickly be applied in order to reduce morbidity, mortality, and ideally viral transmission. By repurposing of broadly active antiviral drugs and compounds that are known to inhibit viral replication of related viruses, several advances could be made in the development of treatment strategies against COVID-19. The nucleoside analog remdesivir, which is known for its potent in vitro activity against Ebolavirus and other RNA viruses, was recently shown to reduce the time to recovery in patients with severe COVID-19. It is to date the only approved antiviral for treating COVID-19. Here, we provide a mechanism and evidence-based comparative review of remdesivir and other repurposed drugs with proven in vitro activity against SARS-CoV-2.
持续的 SARS-CoV-2 大流行强调了需要有效的抗病毒药物，以便能够迅速应用，从而降低发病率、死亡率，并理想情况下降低病毒传播。通过重新利用广泛有效的抗病毒药物和已知可抑制相关病毒复制的化合物，可以在开发针对 COVID-19 的治疗策略方面取得一些进展。核苷类似物瑞德西韦以其对埃博拉病毒和其他 RNA 病毒的强大体外活性而闻名，最近的研究表明，它可以缩短重症 COVID-19 患者的康复时间。它是迄今为止唯一批准用于治疗 COVID-19 的抗病毒药物。在这里，我们提供了瑞德西韦和其他已证明具有体外抗 SARS-CoV-2 活性的已重新利用药物的机制和基于证据的比较综述。
